Napo Pharmaceuticals appoints new chief medical officer

Gastrointestinal pharmaceutical company Napo Pharmaceuticals recently introduced Darlene Horton, MD, as its new chief medical officer, according to a May 26 press release.

Advertisement

In her new role, Dr. Horton will support the company in its phase 3 clinical trial of its crofelemer drug meant to prevent diarrhea in cancer patients receiving cancer therapy.

Dr. Horton received her medical degree from the University of Florida in Gainesville and completed a residency and fellowship at the University of California San Francisco. She has previous leadership experience at various healthcare companies, including being the CMO of Coherus BioSciences, Itero Biopharmaceuticals and SMC Biotechnology.

Napo Pharmaceuticals is a subsidiary of Jaguar Health, based in San Francisco.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.